Liquid Biopsy in Paraneoplastic Neurological Syndromes
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHeinrich-Heine University, Duesseldorf
About this trial
The main objective of the study is to assess whether circulating tumor cells (CTCs) can be detected in the peripheral blood of patients with paraneoplastic neurological syndromes (PNS) by diagnostic leukapheresis (DLA) combined with the CELLSEARCH® System during clinical routine workup. If CTCs can be identified, a detailed molecular genetic analysis will be performed to characterize mutations in oncogenes and tumor suppressor genes. In addition, the study aims to analyze cell-free DNA (cfDNA) in serum of patients.
Individuals with PNS and high- or intermediate-risk or GAD65-antibodies with a detectable tumor (PNS+T), PNS patients with high- or intermediate-risk or GAD65-antibodies without detectable tumor (PNS w/o T), and matched tumor patients without PNS (T w/o PNS) will be included in the study.
Eligibility criteria
Qualifiers
Patients with paraneoplastic neurological syndromes (PNS) and high- or intermediate-risk or GAD65-antibodies or
Patients with peripheral tumors without PNS
Disqualifiers
Age below 18 years at the time of inclusion.
Any mental condition impairing the capacity to provide informed consent.
Presence of contraindications to DLA.
Trial design
Treatments tested in this trial
- CTC & ctDNA analysis
Treatment groups
60 Participants
are divided into 3 treatment groupsSponsors and collaborators
Heinrich-Heine University, Duesseldorf
Lead sponsor
University of Regensburg
Collaborator
Universität Münster
Collaborator
Erasmus Medical Center
Collaborator
Medical University of Graz
Collaborator
Source ClinicalTrials.gov